Sarepta Therapeutics Inc (SRPT)

Working capital turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496	380,833	365,135	344,580
Total current assets	US$ in thousands	2,464,860	2,579,330	2,450,850	2,472,610	2,488,380	2,557,860	2,625,930	2,469,300	2,530,950	2,604,100	2,185,310	2,265,220	2,271,350	2,485,200	2,322,670	2,459,420	2,547,350	1,468,910	1,362,300	1,427,420
Total current liabilities	US$ in thousands	608,709	653,659	450,743	498,654	536,884	619,604	602,916	545,566	454,962	452,733	373,443	425,022	364,736	416,026	378,388	354,896	306,429	264,767	215,856	162,089
Working capital turnover		0.76	0.65	0.55	0.51	0.50	0.48	0.43	0.43	0.37	0.33	0.36	0.33	0.30	0.26	0.25	0.21	0.18	0.32	0.32	0.27

March 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $1,403,300K ÷ ($2,464,860K – $608,709K)
= 0.76

Sarepta Therapeutics Inc's working capital turnover has displayed fluctuations over the period from December 2019 to March 2024. The working capital turnover ratio measures the efficiency of a company in utilizing its working capital to generate sales revenue.

The trend indicates that Sarepta Therapeutics Inc has improved its working capital turnover ratio over time, with a noticeable increase from 0.18 in March 2020 to 0.76 in March 2024. This indicates that the company has been able to generate more revenue for each unit of working capital invested.

However, it is important to note that the ratio fluctuated during this period, which may reflect changes in the company's operations, sales, and management of working capital. For example, the ratio decreased from 0.50 in March 2023 to 0.48 in December 2022 before showing an upward trend.

Overall, Sarepta Therapeutics Inc's working capital turnover has shown improvement, reflecting better efficiency in managing its working capital to support sales activities. The company's ability to sustain and further enhance this trend will be crucial for its overall financial health and operational effectiveness.